Simply Wall St.
Alphabet Faces Gemini Lawsuit While Deepening Healthcare AI Role With CVS
📉
AI Sentiment
Negative
3/10
- Home
- CVS
as of 03-06-2026 3:52pm EST
$77.99
$0.70
-0.90%
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
| Founded: | 1963 | Country: | United States |
| Employees: | N/A | City: | WOONSOCKET |
| Market Cap: | 100.7B | IPO Year: | 1994 |
| Target Price: | $94.33 | AVG Volume (30 days): | 7.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 1.39 | EPS Growth: | -62.02 |
| 52 Week Low/High: | $58.35 - $85.15 | Next Earning Date: | 05-07-2026 |
| Revenue: | $402,067,000,000 | Revenue Growth: | 7.85% |
| Revenue Growth (this year): | 2.45% | Revenue Growth (next year): | 4.56% |
| P/E Ratio: | 56.79 | Index: | |
| Free Cash Flow: | 7.8B | FCF Growth: | +23.41% |
AI-Powered CVS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 75.30%
75.30%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 10, 2026 · 100% conf.
AI Prediction SELL
1D
-1.79%
$74.34
5D
-3.01%
$73.42
20D
-6.21%
$71.00
Price: $75.70 Prob +5D: 0% AUC: 1.000
0000064803-26-000009
cvs-202602100000064803false00000648032026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):February 10, 2026
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
One CVS Drive, Woonsocket, Rhode Island 02895 (Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (401)765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareCVSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On February 10, 2026, CVS Health Corporation issued a press release announcing results for the three months and full year ended December 31, 2025. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
99.1Press Release of CVS Health Corporation dated February 10, 2026 (furnished under Item 2.02).
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CVS HEALTH CORPORATION
Date:February 10, 2026By:/s/ Brian O. Newman Brian O. Newman Executive Vice President and Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 29, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 29, 2025
0000064803-25-000036
cvs-202510290000064803false00000648032025-10-292025-10-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):October 29, 2025
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
One CVS Drive, Woonsocket, Rhode Island 02895 (Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (401) 765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareCVSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2025, CVS Health Corporation issued a press release announcing results for the three months ended September 30, 2025. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
99.1Press Release of CVS Health Corporation dated October 29, 2025 (furnished under Item 2.02)
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CVS HEALTH CORPORATION
Date:October 29, 2025By:/s/ Brian O. Newman Brian O. Newman Executive Vice President and Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Jul 31, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 31, 2025
0000064803-25-000023
cvs-202507310000064803false00000648032025-07-312025-07-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):July 31, 2025
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040 (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)
One CVS Drive, Woonsocket, Rhode Island 02895 (Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (401) 765-1500
Former name or former address, if changed since last report: N/A
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.01 per shareCVSNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On July 31, 2025, CVS Health Corporation issued a press release announcing results for the three months ended June 30, 2025. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
99.1Press Release of CVS Health Corporation dated July 31, 2025 (furnished under Item 2.02)
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CVS HEALTH CORPORATION
Date:July 31, 2025By:/s/ Brian O. Newman Brian O. Newman Executive Vice President and Chief Financial Officer
Latest CVS Health Corporation News
CVS Breaking Stock News: Dive into CVS Ticker-Specific Updates for Smart Investing
Simply Wall St.
CVS Health Bets On Health100 To Unite AI And Consumer Care
📈
AI Sentiment
Highly Positive
8/10
GuruFocus.com
CVS launches Health100 AI platform with Google Cloud partnership
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
CVS Health, Google Cloud Collaborate to Launch AI-Powered Health Engagement Platform
➖
AI Sentiment
Neutral
5/10
Reuters
CVS taps Google Cloud to roll out AI-powered health platform
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
CVS Health and Google Cloud announce new strategic partnership to reimagine healthcare consumer engagement and experiences
📈
AI Sentiment
Highly Positive
9/10
Compare CVS vs Leading Stocks
See how CVS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CVS CVS Health Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.